NCT07513454 2026-04-07
A Phase 2 Study of HW211026 in Participants With Actinic Keratosis
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Phase 2 Not yet recruiting
Clinical Trials
335 trialsNCT05662202 2026-04-03
Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp
Biofrontera Inc.
Phase 3 Active not recruiting
NCT07286318 2026-04-02
A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients
University of Pittsburgh
Phase EARLY_PHASE1 Not yet recruiting
NCT06135415 2026-03-25
TirbAKare
Almirall, S.A.
Phase 3 Completed
NCT07144345 2026-03-05
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
Sun Pharmaceutical Industries Limited
Phase 3 Active not recruiting
NCT07428941 2026-02-24
LegitHealth PH
AI Labs Group S.L
Completed
NCT05923060 2026-02-20
Imaging Techniques to Monitor Photosensitizer and sO2 Levels During Photodynamic Therapy of Actinic Keratoses
Case Comprehensive Cancer Center
Phase 2 Completed
NCT07144852 2026-02-20
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
Sun Pharmaceutical Industries Limited
Phase 3 Active not recruiting
NCT07401277 2026-02-10
Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum
West Virginia University
Phase 1 Not yet recruiting
NCT06888362 2026-01-28
Trial to Investigate GZ21T in Healthy Volunteers
Genzada Pharmaceuticals USA, Inc.
Phase 1 Completed
NCT07340697 2026-01-27
Evaluate RLS-1496 Topical Cream for Actinic Keratosis
Rubedo Life Sciences, Inc.
Phase 1/2 Recruiting
NCT05212246 2026-01-22
B3C
VA Office of Research and Development
Phase 3 Not yet recruiting
NCT07335003 2026-01-12
Study of the Photoprotection and Prevention of Actinic Damage With Anthelios Fluide 100 KA+ UVMune 400 in Patients With Multiple Actinic Keratoses
Cosmetique Active International
Phase NA Recruiting
NCT07318675 2026-01-06
A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Phase 1 Recruiting
NCT07053852 2026-01-02
Activation of Ameluz With BBL HEROic for the Treatment of Actinic Keratoses and Photodamage
Rochester Dermatologic Surgery
Phase 1 Completed
NCT06778434 2025-12-22
The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans
VA Office of Research and Development
Phase 2 Recruiting
NCT07290959 2025-12-18
Indoor Daylight Photodynamic Therapy is an Effective, First-line Treatment for AK, But Its Feasibility is Limited by the Time Required for the Illumination (2 Hours). Our Objective Was to Evaluate the Efficacy of Idl-PDT With an Illumination Time of 1 Hour Versus 2 Hours in the Treatment of Scalp AK
San Salvatore Hospital of L'Aquila
Phase NA Completed
NCT07273656 2025-12-09
TIRBACRYO
University Hospital, Lille
Phase 3 Not yet recruiting
NCT06461442 2025-12-05
Efficacy and Safety of Cryotherapy Versus 5-Fluorouracil in the Treatment of Actinic Keratosis
University of California, Davis
Phase 4 Enrolling by invitation
NCT04223570 2025-11-21
Portable Measurement of Protoporphyrin IX in the Skin
Dartmouth-Hitchcock Medical Center
Completed
NCT06027619 2025-10-23
Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses
Case Comprehensive Cancer Center
Phase 2 Completed
NCT05699603 2025-09-24
Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients
University of Arizona
Phase 2 Active not recruiting
NCT07049068 2025-09-15
Comparison of Nicotinamide Treatments for Actinic Keratosis
Federal University of Rio Grande do Sul
Phase 1 Completed
NCT07137819 2025-08-22
EXACT-1
Aresus Pharma GmbH
Phase 3 Recruiting
NCT02373371 2025-07-29
Actinic Keratoses Treatment With Metvix® in Combination With Light
University Hospital, Limoges
Phase 3 Completed
NCT06319794 2025-07-18
Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis
TORQUR
Phase 2 Completed
NCT06385340 2025-07-11
Investigation of the Effect of Lipikar Baume AP+M
CentroDerm GmbH
Phase NA Recruiting
NCT06648447 2025-07-09
Tir2401
CentroDerm GmbH
Recruiting
NCT06321003 2025-05-23
SYMILIS OCT
University of Palermo
Recruiting
NCT06499415 2025-05-11
CALM
Maastricht University Medical Center
Phase 4 Recruiting
NCT04429308 2025-05-08
PDT vs Peels for Treatment of Actinic Keratoses
Northwestern University
Phase 2 Not yet recruiting
NCT04329221 2025-05-07
Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients
Massachusetts General Hospital
Phase 2 Withdrawn
NCT04642287 2025-05-07
Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients
Massachusetts General Hospital
Phase 2 Withdrawn
NCT00472459 2025-04-18
Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Galderma R&D
Phase 3 Completed
NCT05976048 2025-04-04
Implementation of Actinic Keratosis Guideline Among General Practitioners.
Maastricht University Medical Center
Active not recruiting
NCT05976061 2025-04-04
High- and Low-risk Actinic Keratosis Referrals to Secondary Care
Maastricht University Medical Center
Active not recruiting
NCT05987553 2025-04-04
The Influence of an E-learning Program on Recognition of Actinic Keratosis
Maastricht University Medical Center
Active not recruiting
NCT06008171 2025-04-04
Patient Decision Aid for the Treatment of Actinic Keratosis
Maastricht University Medical Center
Phase NA Active not recruiting
NCT06014697 2025-04-04
OCT and Invasion in Cutaneous Skin Lesions
Maastricht University Medical Center
Completed
NCT03906253 2025-03-25
Effectiveness of Fractionated Laser Resurfacing to Protect Geriatric Skin From Actinic Neoplasia
Wright State University
Phase NA Recruiting
NCT01820260 2025-03-13
Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis
LEO Pharma
Phase 1/2 Completed
NCT02549352 2025-03-13
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
LEO Pharma
Phase 3 Completed
NCT03115476 2025-03-11
A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
LEO Pharma
Phase 3 Terminated
NCT01541553 2025-03-10
A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp
LEO Pharma
Phase 3 Completed
NCT01600014 2025-03-10
Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp
LEO Pharma
Phase 3 Completed
NCT01998984 2025-03-10
Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
LEO Pharma
Phase 2 Completed
NCT02305888 2025-03-10
Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively
LEO Pharma
Phase 2 Completed
NCT02361216 2025-03-10
Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest
LEO Pharma
Phase 3 Completed
NCT02547233 2025-03-10
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
LEO Pharma
Phase 3 Completed
NCT02547363 2025-03-10
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
LEO Pharma
Phase 3 Completed